Showing results (681-690 of 782) with videos related to
Sort By:
Pageof 79
Blood|August 5, 2004
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell functionAbie Craiu, Yoriko Saito, Ana Limon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.Blood Advances|July 18, 2022
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.Blood|May 22, 2025
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAsEugenio Morelli, Anil Aktas-Samur, Domenico Maisano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple MyelomaEugenio Morelli, Caroline Fidalgo Ribeiro, Silvia D Rodrigues, et al.Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.Pageof 79